US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

157.47

+1.230.79%

Post-market: 157.00-0.4700-0.30%17:08 EDT

Volume:418.21K

Turnover:66.36M

Market Cap:507.76M

PE:- -

High:161.26

Open:157.46

Low:155.50

Close:156.24

52wk High:198.18

52wk Low:32.55

Shares:3.22M

Float Shares:3.22M

Volume Ratio:0.60

T/O Rate:12.97%

Dividend:1.34

Dividend Rate:0.85%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Analysts Offer Insights on Healthcare Companies: Canopy Growth (CGC) and Doximity (DOCS)

Lantheus announces three-month extension of LNTH-2501 PDUFA date

Press Release: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates

UPDATE – Pennant Group to Participate in the 2026 Oppenheimer Annual Healthcare Conference

FDA Rejects Aldeyra's Dry Eye Drug For Third Time, Stock Crashes 68%

Buy Rating on BPL-003 Underpinned by Strong Phase 2a Efficacy, De-Risked Phase 3 Program, and Upside to $25 Target Price

Health Care Roundup: Market Talk

Fidia Expands Share Capital After GGHL Converts New Tranche of Bonds

UFP Technologies to Present and Host 1X1 Investor Meetings at the KeyBanc Capital Markets Virtual Healthcare Forum

Expanding ANKTIVA’s NMIBC Opportunity: NCCN Endorsement, FDA Flexibility, and Strengthening Long‑Term Prospects for ImmunityBio

Analysts Offer Insights on Healthcare Companies: NeurAxis, Inc. (NRXS), Argenx Se (ARGX) and Teladoc (TDOC)

Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Assertio Therapeutics (ASRT) and LENSAR (LNSR)

Innorna Announces FDA Clearance of IND for IN026, Advancing mRNA-based Therapies into Chronic Metabolic Diseases

FDA-Approved Yield Boost For ASCENIV Might Change The Case For Investing In ADMA Biologics (ADMA)

Simply Wall St.

FDA Declines Approval for Aldeyra's Eye Disease Treatment, Stock Plummets 65%

Sector Update: Health Care Stocks Mixed Premarket Tuesday

MT Newswires Live

FDA issues Aldeyra CRL saying reproxalap NDA failed to demonstrate efficacy

How Did the FDA Shatter Investor Confidence In Aldeyra Therapeutics Stock (ALDX) Today?

FDA Issues Second Complete Response Letter for Reproxalap

Analysts Conflicted on These Healthcare Names: Cochlear (OtherCHEOF), Universal Health (UHS) and Vera Therapeutics (VERA)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/LABU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":157.47,"timestamp":1773777600000,"preClose":156.24,"halted":0,"volume":418206,"hourTrading":{"tag":"盘后","latestPrice":157,"preClose":157.47,"latestTime":"17:08 EDT","volume":673,"amount":105954.3607,"timestamp":1773781710457,"change":-0.47,"changeRate":-0.002985,"amplitude":0.010161},"delay":0,"changeRate":0.00787250384024571,"floatShares":3224486,"shares":3224486,"eps":0,"marketStatus":"Post-Mkt","change":1.23,"latestTime":"03-17 17:11:46 EDT","open":157.46,"high":161.26,"low":155.5,"amount":66362801.64288,"amplitude":0.036866,"askPrice":157.8,"askSize":200,"bidPrice":156.6,"bidSize":100,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1773792000000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":156.24,"sharesOutstanding":3074486,"nav":149.06,"aum":480642683.13,"dividendRate":0.008533,"bidAskSpread":0.002274,"preHourTrading":{"tag":"盘前","latestPrice":157.98,"preClose":156.24,"latestTime":"09:28 EDT","volume":3731,"amount":579161.18988,"timestamp":1773754129536,"change":1.74,"changeRate":0.011137,"amplitude":0.022721},"postHourTrading":{"tag":"盘后","latestPrice":157,"preClose":157.47,"latestTime":"17:08 EDT","volume":673,"amount":105954.3607,"timestamp":1773781710457,"change":-0.47,"changeRate":-0.002985,"amplitude":0.010161},"volumeRatio":0.598861,"impliedVol":1.0319,"impliedVolPercentile":0.8526},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":3224486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.598861,"shares":3224486,"dividePrice":1.3437,"high":161.26,"amplitude":0.036866,"preClose":156.24,"low":155.5,"week52Low":32.55,"pbRate":"--","week52High":198.18,"institutionHeld":0,"latestPrice":157.47,"committee":-0.333333,"eps":0,"divideRate":0.008533,"volume":418206,"delay":0,"ttmEps":0,"open":157.46,"prevYearClose":159.39,"prevWeekClose":148.85,"prevMonthClose":172.7,"prevQuarterClose":159.39,"fiveDayClose":171.5,"twentyDayClose":162.07,"sixtyDayClose":156.51},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620403064","title":"Analysts Offer Insights on Healthcare Companies: Canopy Growth (CGC) and Doximity (DOCS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620403064","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620403064?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:40","pubTimestamp":1773780027,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Canopy Growth (CGC – Research Report) and Doximity (...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-canopy-growth-cgc-and-doximity-docs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-canopy-growth-cgc-and-doximity-docs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4167","DOCS","BK4137","LU0029874061.USD","BK4588","CGC","BK4585","XLV","BK4613","LU0128526141.USD","BK4581","LABU","HCSG","XBI","BK4557","BK4539","BK4007","BK4551"],"gpt_icon":0},{"id":"2620403180","title":"Lantheus announces three-month extension of LNTH-2501 PDUFA date","url":"https://stock-news.laohu8.com/highlight/detail?id=2620403180","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620403180?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:22","pubTimestamp":1773778920,"startTime":"0","endTime":"0","summary":"Lantheus (LNTH) announced that the FDA has extended its review of the new drug application for LNTH-2501 by three months to June 29. The extension ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lantheus-announces-three-month-extension-of-lnth-2501-pdufa-date-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lantheus-announces-three-month-extension-of-lnth-2501-pdufa-date-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4588","BK4198","LNTH","BK4585"],"gpt_icon":0},{"id":"2620682408","title":"Press Release: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2620682408","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620682408?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:05","pubTimestamp":1773777900,"startTime":"0","endTime":"0","summary":"Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough. On track to initiate a Phase 2b clinical trial for the treatment of patients with refractory chronic cough in the second quarter of 2026. Company ended 2025 with $188.3 million in cash, cash equivalents and marketable securities, with expected cash runway into 2028. Management to host a conference call and webcast today at 4:30 p.m. ET. NEW HAVEN, Conn., March 17, 2026  -- Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio  for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis , non-IPF interstitial lung disease , and refractory chronic cough , today announced financial results for the fourth quarter and year ended December 31, 2025, and provided business updates.overall alignment on the plan for the remai","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","RCC","BK4585","BK4539","TRVI","BK4604","LABU","BK4139","TM","BK4588","LENZ","BK4555","BK4099","BK4007"],"gpt_icon":0},{"id":"2620477841","title":"UPDATE – Pennant Group to Participate in the 2026 Oppenheimer Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2620477841","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620477841?lang=en_us&edition=fundamental","pubTime":"2026-03-18 01:40","pubTimestamp":1773769200,"startTime":"0","endTime":"0","summary":"EAGLE, Idaho, March  17, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, announ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/17/3257551/0/en/UPDATE-Pennant-Group-to-Participate-in-the-2026-Oppenheimer-Annual-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4185","BK4581","HCSG","XBI","XLV","BK4137","BK4588","LABU","LU0128526141.USD","PNTG","LU0029874061.USD","BK4127","BK4196","OPY"],"gpt_icon":0},{"id":"2620471517","title":"FDA Rejects Aldeyra's Dry Eye Drug For Third Time, Stock Crashes 68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620471517","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620471517?lang=en_us&edition=fundamental","pubTime":"2026-03-18 00:27","pubTimestamp":1773764820,"startTime":"0","endTime":"0","summary":"The company received an FDA Complete Response Letter  regarding its New Drug Application for reproxalap, an investigational treatment for dry eye disease.The CRL stated that there is “a lack of substantial evidence consisting of adequate and well-controlled investigations.”The CRL indicated that Aldeyra failed to provide substantial evidence demonstrating the efficacy of reproxalap in adequately controlled studies, raising significant concerns about the reliability of positive findings.The FDA did not recommend further trials but suggested exploring the reasons for the failures in certain trials and identifying specific populations where the drug may be effective.In a statement, Aldeyra’s CEO, Todd Brady, emphasized the urgency of working with the FDA to enable market access for reproxalap, viewing it as a potential breakthrough treatment for dry eye disease.As of December 31, 2025, the company reported having $70 million in cash and equivalents, expected to support operations into 202","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/17/Eye-In-Close-Up-With-Light-Blue-Iris-Det_0.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/17/Eye-In-Close-Up-With-Light-Blue-Iris-Det_0.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/fda/26/03/51303684/fda-rejects-aldeyras-dry-eye-drug-for-third-time-stock-crashes-68","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/26/03/51303684/fda-rejects-aldeyras-dry-eye-drug-for-third-time-stock-crashes-68","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4585","LU1815336091.USD","LABU","CRL","IE00BFMHRM44.USD","LU0128526141.USD","BK4588","BK4121","LU0029874061.USD","LU0757428866.USD","LU0390134368.USD","BK4530"],"gpt_icon":0},{"id":"2620471538","title":"Buy Rating on BPL-003 Underpinned by Strong Phase 2a Efficacy, De-Risked Phase 3 Program, and Upside to $25 Target Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2620471538","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620471538?lang=en_us&edition=fundamental","pubTime":"2026-03-18 00:25","pubTimestamp":1773764716,"startTime":"0","endTime":"0","summary":"Atai Beckley N.V., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C. Wainwright reite...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-on-bpl-003-underpinned-by-strong-phase-2a-efficacy-de-risked-phase-3-program-and-upside-to-25-target-price-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-on-bpl-003-underpinned-by-strong-phase-2a-efficacy-de-risked-phase-3-program-and-upside-to-25-target-price-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4581","XLV","XBI","BK4588","BK4585"],"gpt_icon":0},{"id":"2620147972","title":"Health Care Roundup: Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2620147972","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620147972?lang=en_us&edition=fundamental","pubTime":"2026-03-18 00:20","pubTimestamp":1773764400,"startTime":"0","endTime":"0","summary":"The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0223 ET - Praram 9 Hospital'searnings growth is likely outperforming the sector's average, Thanachart Securities' Siriporn Arunothai says in a report. Drivers include robust growth of foreign patient flows and high-intensity healthcare, the analyst says. The Thailand hospital has been active in attracting Middle Eastern patients, says the brokerage, which projects the foreign-patient segment's revenue contribution to increase to 31% by 2028 from 26% in 2025. However, the brokerage trims its 2026-2028 earnings estimates for the company by 1%-3% to partly reflect the two-month impact from the Middle East conflict. It lowers the stock's target price to THB24.00 from THB26.00 with an unchanged buy rating. Shares are 0.6% lower at","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","XBI","BK4588","LABU","BK4585","BK4581"],"gpt_icon":0},{"id":"2620479299","title":"Fidia Expands Share Capital After GGHL Converts New Tranche of Bonds","url":"https://stock-news.laohu8.com/highlight/detail?id=2620479299","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620479299?lang=en_us&edition=fundamental","pubTime":"2026-03-18 00:04","pubTimestamp":1773763488,"startTime":"0","endTime":"0","summary":"The latest update is out from Fidia Spa ( ($IT:FDA) ). Fidia S.p.A. has announced that Global Growth Holding Limited has converted three bonds from...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fidia-expands-share-capital-after-gghl-converts-new-tranche-of-bonds?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fidia-expands-share-capital-after-gghl-converts-new-tranche-of-bonds?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4588","BK4585","VGT"],"gpt_icon":0},{"id":"2620328476","title":"UFP Technologies to Present and Host 1X1 Investor Meetings at the KeyBanc Capital Markets Virtual Healthcare Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2620328476","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620328476?lang=en_us&edition=fundamental","pubTime":"2026-03-17 23:00","pubTimestamp":1773759600,"startTime":"0","endTime":"0","summary":"NEWBURYPORT, Mass., March  17, 2026  -- UFP Technologies, Inc. , a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today announced that President Mitchell Rock and Chief Financial Officer Ron Lataille will participate in a virtual fireside chat at the upcoming KeyBanc Capital Markets Virtual Healthcare Forum on March 18, 2026, beginning at approximately 10:30 AM ET. About UFP Technologies, Inc.UFP Technologies is a contract development and manufacturing organization that specializes in single-use and single-patient medical devices. UFP is a vital link in the medical device supply chain and a valued outsourcing partner to many of the world's top medical device manufacturers. The Company’s single-use and single-patient devices and components are used in a wide range of medical devices and packaging for minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/17/3257427/0/en/UFP-Technologies-to-Present-and-Host-1X1-Investor-Meetings-at-the-KeyBanc-Capital-Markets-Virtual-Healthcare-Forum.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4179","FET","BK4588","LU0128526141.USD","LU0029874061.USD","BK4181","XLV","BK4581","BK4218","BK4137","HCSG","HST","LABU","BK4585"],"gpt_icon":0},{"id":"2620758824","title":"Expanding ANKTIVA’s NMIBC Opportunity: NCCN Endorsement, FDA Flexibility, and Strengthening Long‑Term Prospects for ImmunityBio","url":"https://stock-news.laohu8.com/highlight/detail?id=2620758824","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620758824?lang=en_us&edition=fundamental","pubTime":"2026-03-17 22:25","pubTimestamp":1773757517,"startTime":"0","endTime":"0","summary":"In a report released today, Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on ImmunityBio, with a price target of $15.00. Andres ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/expanding-anktivas-nmibc-opportunity-nccn-endorsement-fda-flexibility-and-strengthening-long‑term-prospects-for-immunitybio-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/expanding-anktivas-nmibc-opportunity-nccn-endorsement-fda-flexibility-and-strengthening-long‑term-prospects-for-immunitybio-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LABU","BK4588"],"gpt_icon":0},{"id":"2620478477","title":"Analysts Offer Insights on Healthcare Companies: NeurAxis, Inc. (NRXS), Argenx Se (ARGX) and Teladoc (TDOC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620478477","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620478477?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:50","pubTimestamp":1773755415,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on NeurAxis, Inc. (NRXS – Research Report), Argenx Se (...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neuraxis-inc-nrxs-argenx-se-argx-and-teladoc-tdoc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neuraxis-inc-nrxs-argenx-se-argx-and-teladoc-tdoc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","BK4548","BK4581","IE00B4R5TH58.HKD","LU1861559042.SGD","LU2324357040.USD","IE00BFTCPJ56.SGD","LU0320765992.SGD","BK4588","IE0002141913.USD","IE0034235188.USD","BK4567","BK4137","XLV","BK4534","BK4167","ARGX","LABU","XBI","BK4504","IE00B2B36J28.USD","BK4139","BK4505","IE0009355771.USD","HCSG","LU0109394709.USD","LU1983260115.SGD","BK4082","LU1861558580.USD","NRXS","BK4585","IE00BJT1NW94.SGD","LU0128526141.USD","TDOC","LU0029874061.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2620405478","title":"Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Assertio Therapeutics (ASRT) and LENSAR (LNSR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620405478","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620405478?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:40","pubTimestamp":1773754806,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Neurosense Therapeutics Ltd. (NRSN – Research Repo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neurosense-therapeutics-ltd-nrsn-assertio-therapeutics-asrt-and-lensar-lnsr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neurosense-therapeutics-ltd-nrsn-assertio-therapeutics-asrt-and-lensar-lnsr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","LU0128526141.USD","BK4588","BK4585","BK4007","ASRT","LABU","HCSG","LNSR","NRSN","XLV","BK4139","BK4082","LU0029874061.USD","XBI","BK4137"],"gpt_icon":0},{"id":"2620420768","title":"Innorna Announces FDA Clearance of IND for IN026, Advancing mRNA-based Therapies into Chronic Metabolic Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2620420768","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620420768?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:30","pubTimestamp":1773754200,"startTime":"0","endTime":"0","summary":"IN026 is a potential first-in-class mRNA therapy for refractory gout, marking the emergence of a new category of mRNA medicines enabled by Innorna's proprietary mRNA–LNP platform.HONG KONG SAR, Chinaand SHENZHEN, China and CAMBRIDGE, Mass., March 17, 2026 /PRNewswire/ -- Innorna, a clinicalstage biotech company advancing RNA medicines, today announced that the U.S. Food and Drug Administration  has cleared its Investigational New Drug  application for IN026, an investigational mRNA-based therapy for refractory gout. The IND clearance enables the company to initiate a Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IN026 in this currently underserved patient population.IN026 delivers mRNA encoding urate oxidase  to the liver to enable systemic uric acid breakdown.\"Refractory gout remains a severely debilitating condition, and existing biologic treatments are limited by immunogenicity, tolerability challenges, and diminishing efficac","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2934528/Innorna_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2934528/Innorna_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/innorna-announces-fda-clearance-of-ind-for-in026-advancing-mrna-based-therapies-into-chronic-metabolic-diseases-302715658.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IND","IND.AU","BK4588","LABU","BK7095"],"gpt_icon":0},{"id":"2620763704","title":"FDA-Approved Yield Boost For ASCENIV Might Change The Case For Investing In ADMA Biologics (ADMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620763704","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620763704?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:21","pubTimestamp":1773753665,"startTime":"0","endTime":"0","summary":"ADMA Biologics recently reported strong 2025 performance driven by higher demand for its immune globulin therapy ASCENIV, alongside improved payer coverage and confidence in long-term plasma supply that together provide clearer visibility into 2026 revenue acceleration.\nThe FDA’s approval of a yield-enhancement manufacturing process is particularly important, as it is expected to lift production efficiency while supporting higher margins and longer-term capital return efforts.\nNow we’ll...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/fda-approved-yield-boost-for-asceniv-might-change-the-case-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/fda-approved-yield-boost-for-asceniv-might-change-the-case-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","US2Y.BOND","US10Y.BOND","US3Y.BOND","US12M.BOND","TLTW","US7Y.BOND","US6M.BOND","LABU","TMF","US30Y.BOND","BK4588","US5Y.BOND","ADMA","BK4139"],"gpt_icon":1},{"id":"1179053917","title":"FDA Declines Approval for Aldeyra's Eye Disease Treatment, Stock Plummets 65%","url":"https://stock-news.laohu8.com/highlight/detail?id=1179053917","media":"Deep News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179053917?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:20","pubTimestamp":1773753627,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics announced on Tuesday that the U.S. Food and Drug Administration (FDA) has declined to approve its drug for treating an eye disease, causing the company's stock to plunge 65% in...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LABU","BK4588"],"gpt_icon":0},{"id":"2620420382","title":"Sector Update: Health Care Stocks Mixed Premarket Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2620420382","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620420382?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:16","pubTimestamp":1773753404,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF  down 0.1% and the iShares Biotechnology ETF  0.4% higher.Eupraxia Pharmaceuticals  shares were up more than 1% after the company said data from its ongoing trial evaluating EP-104GI for eosinophilic esophagitis treatment showed 59% of patients achieved clinical remission at 12 weeks.Monte Rosa Therapeutics  stock was down 1% after the company reported that it swung to a Q4 net loss as collaboration revenue declined during the period.Lensar  shares were down more than 24% after the company said it has reached an agreement with Alcon  to terminate their planned merger.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4198","BK4539","GLUE","IBB","ALC","ALC.AU","LU1804176565.USD","BK7094","LU2265009873.SGD","LABU","BK4581","XBI","XLV","BK4082","BK4588","EPRX","LNSR","BK4534","BK4139","BK4585"],"gpt_icon":0},{"id":"2620695420","title":"FDA issues Aldeyra CRL saying reproxalap NDA failed to demonstrate efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2620695420","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620695420?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:11","pubTimestamp":1773753069,"startTime":"0","endTime":"0","summary":"Aldeyra (ALDX) announced receipt of a complete response letter, or CRL, from the FDA for the new drug application, or NDA, of reproxalap, an invest...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fda-issues-aldeyra-crl-saying-reproxalap-nda-failed-to-demonstrate-efficacy-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fda-issues-aldeyra-crl-saying-reproxalap-nda-failed-to-demonstrate-efficacy-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4588","IE00BFMHRM44.USD","LU0390134368.USD","LU0757428866.USD","BK4585","LABU","CRL","BK4121","BK4139","ALDX","LU0029874061.USD","BK4530","LU1815336091.USD"],"gpt_icon":0},{"id":"2620203004","title":"How Did the FDA Shatter Investor Confidence In Aldeyra Therapeutics Stock (ALDX) Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2620203004","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620203004?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:10","pubTimestamp":1773753025,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics stock fell hard on Tuesday after it received a CRL from the FDA.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/how-the-fda-shattered-investor-confidence-in-aldeyra-therapeutics-stock-aldx-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/how-the-fda-shattered-investor-confidence-in-aldeyra-therapeutics-stock-aldx-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4588","BK4139","ALDX","BK4585"],"gpt_icon":0},{"id":"2620342755","title":"FDA Issues Second Complete Response Letter for Reproxalap","url":"https://stock-news.laohu8.com/highlight/detail?id=2620342755","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620342755?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:58","pubTimestamp":1773752309,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics ( ($ALDX) ) has shared an update. On March 17, 2026, Aldeyra Therapeutics announced that the U.S. Food and Drug Administration...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fda-issues-second-complete-response-letter-for-reproxalap?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fda-issues-second-complete-response-letter-for-reproxalap?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","LABU"],"gpt_icon":0},{"id":"2620342250","title":"Analysts Conflicted on These Healthcare Names: Cochlear (OtherCHEOF), Universal Health (UHS) and Vera Therapeutics (VERA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620342250","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620342250?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:30","pubTimestamp":1773750629,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cochlear (CHEOF – Research Report), Universal Heal...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-cochlear-othercheof-universal-health-uhs-and-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-cochlear-othercheof-universal-health-uhs-and-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4185","BK4588","LABU","BK4139","VERA","LU2324357040.USD","HCSG","LU0029874061.USD","UHS","BK4581","BK4539","BK4585","BK4137","XLV","XBI"],"gpt_icon":0}],"pageSize":20,"totalPage":22,"pageCount":1,"totalSize":422,"code":"91000000","status":"200"}]}}